- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Norvir
Synonyms :
Class :
HIV, Protease inhibitors
Dosage forms & Strengths:
Adult:
Capsule:
100 mg
Tablet:
100 mg
Oral solution:
80 mg/ml
Oral powder:
100 mg/packet
For less than 12 years:
300 mg orally every 12 hours; increase by 100-600 mg every 12 hours for 5 days as per tolerance
For more than 12 years:
300 mg orally every 12 hours; increase by 100-600 mg every 12 hours for 5 days as per tolerance
dasatinib may enhance the QTc-prolonging effect of QT-prolonging
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with doxepin-containing products
may increase the QTc-prolonging effect of QT-prolonging Agents
dronedarone: they may increase the QTc-prolonging effect of QTc-prolonging miscellaneous agents
gilteritinib: they may increase the QTc-prolonging effect of QTc-prolonging agents
halofantrine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
osimertinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
pentamidine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may enhance the QTc-prolonging effect of each other when combined
may enhance the QTc-prolonging effect of each other when combined
It may enhance the serum concentration when combined with clobetasone
when both drugs are combined, there may be an increased level of serum concentration of vincristine
when both drugs are combined, there may be an increased level of serum concentration of paclitaxel
the effect of ombitasvir/paritaprevir/ritonavir is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
ritonavir increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ritonavir
ritonavir increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
ritonavir increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
it increases the effect or level of palbociclib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
Ritonavir may reduce the therapeutic effects of Zidovudine, avoid combination
Ritonavir may reduce the therapeutic effects of Tenofovir alafenamide, avoid a combination
may have an increased QTc-prolonging effect when combined with levoketoconazole
may have an increased QTc-prolonging effect when combined with nilotinib
May increase the QTc-prolonging effect of QT-prolonging Agents
may increase the QTc-prolonging effect of QT-prolonging Agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
pazopanib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
quetiapine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ribociclib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
it may decrease the serum concentration of Estrogen Derivatives
bazedoxifene/conjugated estrogens
it may decrease the serum concentration of Estrogen Derivatives
it may decrease the serum concentration of Estrogen Derivatives
it may decrease the serum concentration of Estrogen Derivatives
it may decrease the serum concentration of Estrogen Derivatives
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
It may enhance the serum concentration when combined with Corticosteroids (ophthalmic)
It may enhance the serum concentration when combined with Corticosteroids (ophthalmic)
It may enhance the serum concentration when combined with Corticosteroids (ophthalmic)
It may enhance the serum concentration when combined with Corticosteroids (ophthalmic)
It may enhance the serum concentration when combined with Corticosteroids (ophthalmic)
It may enhance the serum concentration when combined with Corticosteroids (ophthalmic)
It may enhance the serum concentration when combined with Corticosteroids (ophthalmic)
It may enhance the serum concentration when combined with Corticosteroids (ophthalmic)
It may enhance the serum concentration when combined with Corticosteroids (ophthalmic)
It may enhance the serum concentration when combined with Corticosteroids (ophthalmic)
It may enhance the serum concentration when combined with Corticosteroids (ophthalmic)
It may enhance the serum concentration when combined with Corticosteroids (ophthalmic)
It may enhance the serum concentration when combined with Corticosteroids (ophthalmic)
It may enhance toxicity when combined with cholic acid by diminishing the elimination
when both drugs are combined, there may be an increased effect of cabozantinib
has a synergistic effect over brentuximab vedotin by showing altered intestinal/hepatic CYP3A4 enzyme metabolism.
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
QT-prolonging Agents may enhance the QTc-prolonging effect of haloperidol
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
May enhances the effects of the other by pharmacodynamic synergism
it may increase the toxicity of each other
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
QT-prolongers increase the effect of QTc-prolongation of haloperidol
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
estrogens esterified/methyltestosterone
may diminish the serum concentration of estrogen derivatives
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
ritonavir, when taken with ixazomib, alters the intestinal/hepatic CYP3A4 enzyme metabolism
it increases the effect or level of finasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
it increases the effect or level of dutasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
>10%:
Increased triglycerides
Diarrhea
Nausea
Taste perversion
Vomiting
Weakness
Increased GGT
1-10%:
Abdominal pain
Anorexia
Dizziness
Dyspepsia
Eosinophilia
Fever
Flatulence
Headache
Insomnia
Increased uric acid
Increased LFTs
Local throat irritation
Malaise
Myalgia
Diaphoresis
Paresthesia
Pharyngitis
Rash
Somnolence
Pharyngitis
<1%:
Ulcerative colitis
Adrenal suppression
Cerebral ischemia
Dementia
Tachycardia
Edema
Leukopenia
Ritonavir is contraindicated in patients hypersensitive to the formulation’s active ingredient and other excipients.
Pregnancy consideration:
Not indicated for pregnant women.
Breastfeeding warnings:
The drug is excreted in breast milk.
Pregnancy category:
Patient information leaflet
Generic Name: Ritonavir
Pronounced: rit-OH-na-vir
Why do we use Ritonavir?
Ritonavir belongs to the category of antivirals. It is a protease inhibitor drug used for the treatment of HIV infection.
ADVERTISEMENT
